Citation: | Please cite this article as: HE SF, JIANG JR, LIU FZ, LIAO HT, XUE YM, ZHENG MR, LI HX, DENG H, WU SL. Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China. J Geriatr Cardiol 2021; 18(7): 523−533. DOI: 10.11909/j.issn.1671-5411.2021.07.003 |
[1] |
Liu F, Xue Y, Liao H, et al. Five-year epidemiological survey of valvular heart disease: changes in morbidity, etiological spectrum and management in a cardiovascular center of Southern China. J Thorac Dis 2014; 6: 1724−1730.
|
[2] |
Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on valvular heart disease. Eur Heart J 2003; 24: 1231−1243. doi: 10.1016/S0195-668X(03)00201-X
|
[3] |
Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357: 470−476. doi: 10.1056/NEJMoa065085
|
[4] |
Hu P, Liu XB, Liang J, et al. A hospital-based survey of patients with severe valvular heart disease in China. Int J Cardiol 2017; 231: 244−247. doi: 10.1016/j.ijcard.2016.11.301
|
[5] |
Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630−634.
|
[6] |
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233−270. doi: 10.1093/ehjci/jev014
|
[7] |
Wasilewski J, Mirota K, Wilczek K, et al. Calcific aortic valve damage as a risk factor for cardiovascular events. Pol J Radiol 2012; 77: 30−34. doi: 10.12659/PJR.883626
|
[8] |
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: e57−e185. doi: 10.1016/j.jacc.2014.02.536
|
[9] |
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 2440−2492. doi: 10.1161/CIR.0000000000000029
|
[10] |
Marmelo FC, Mateus SM, Pereira AJ. Association of aortic valve sclerosis with previous coronary artery disease and risk factors. Arq Bras Cardiol 2014; 103: 398−402.
|
[11] |
Sliwa K, Carrington M, Mayosi BM, et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J 2010; 31: 719−727. doi: 10.1093/eurheartj/ehp530
|
[12] |
Demirbağ R, Sade LE, Aydın M, et al. The Turkish registry of heart valve disease. Turk Kardiyol Dern Ars 2013; 41: 1−10. doi: 10.5543/tkda.2013.71430
|
[13] |
Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol 2014; 30: 962−970. doi: 10.1016/j.cjca.2014.03.022
|
[14] |
Pasca I, Dang P, Tyagi G, Pai RG. Survival in patients with degenerative mitral stenosis: results from a large retrospective cohort study. J Am Soc Echocardiogr 2016; 29: 461−469. doi: 10.1016/j.echo.2015.12.012
|
[15] |
Chen HY, Engert JC, Thanassoulis G. Risk factors for valvular calcification. Curr Opin Endocrinol Diabetes Obes 2019; 26: 96−102. doi: 10.1097/MED.0000000000000471
|
[16] |
Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994; 15: 865−870. doi: 10.1093/oxfordjournals.eurheartj.a060602
|
[17] |
Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59: 998−999. doi: 10.1016/0002-9149(87)91144-1
|
[18] |
Hsu SY, Hsieh IC, Chang SH, et al. Aortic valve sclerosis is an echocardiographic indicator of significant coronary disease in patients undergoing diagnostic coronary angiography. Int J Clin Pract 2005; 59: 72−77. doi: 10.1111/j.1368-504X.2005.00342.x
|
[19] |
Bouchareb R, Boulanger MC, Tastet L, et al. Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. Eur Heart J 2019; 40: 1362−1373. doi: 10.1093/eurheartj/ehy696
|
[20] |
Uchida S, Kumagai T, Chang WX, et al. Time to target uric acid to retard chronic kidney disease progression. Contrib Nephrol 2018; 192: 56−68.
|
[21] |
Fox CS, Larson MG, Vasan RS, et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol 2006; 17: 521−527. doi: 10.1681/ASN.2005060627
|
[22] |
Mehta T, Nuccio E, McFann K, et al. Association of uric acid with vascular stiffness in the framingham heart study. Am J Hypertens 2015; 28: 877−883. doi: 10.1093/ajh/hpu253
|